Literature DB >> 30777162

Long-Term Effectiveness of a Lifestyle Intervention: A Pragmatic Community Trial to Prevent Metabolic Syndrome.

Davood Khalili1, Samaneh Asgari1, Mojtaba Lotfaliany2, Neda Zafari3, Farzad Hadaegh3, Amir-Abbas Momenan3, Armin Nowroozpoor3, Firoozeh Hosseini-Esfahani4, Parvin Mirmiran5, Parisa Amiri6, Fereidoun Azizi7.   

Abstract

INTRODUCTION: The purpose of this study is to evaluate the long-term effectiveness of a community-based lifestyle education on primary prevention of metabolic syndrome in a middle-income country. STUDY
DESIGN: This study followed 3,180 individuals free of metabolic syndrome who were under the coverage of three health centers in Tehran from 1999 until 2015. They were undergoing triennial examinations resulting in four re-exams. People in one of three areas received interventions consisting of family-, school-, and community-based educational programs, including a face-to-face educational session at baseline. Data were analyzed considering the incidence of metabolic syndrome at each re-exam and also repeated-measure analysis including all re-exams together. Weighting was considered to correct selection bias because of loss to follow-up. Data were analyzed in 2017.
RESULTS: After 3 years, 149 of 852 participants in the intervention and 471 of 2,328 people in control area developed metabolic syndrome at first re-exam resulting in a RR of 0.78 (95% CI=0.67, 0.92). The difference between groups remained unchanged up to the 6-year follow-up (RR=0.79, 95% CI=0.66, 0.93, at second re-exam), but disappeared during the third and fourth re-exams (RR=1.04, 95% CI=0.91, 1.18 and RR=1.03, 95% CI=0.91, 1.16, respectively). Marginal models for longitudinal data showed a significant interaction between intervention and time of re-exams. Further analyses showed that the effect of the intervention might have been rooted in improvement of lipid profile and glucose level.
CONCLUSIONS: In a middle-income country, face-to-face educational sessions followed by a long-term maintenance community-level educational program could reduce the risk of metabolic syndrome for up to 6 years. A booster face-to-face session is recommended to retain this preventive effect. TRIAL REGISTRATION: This study is registered at Iran Registry for Clinical Trials (http://irct.ir) IRCT138705301058N1.
Copyright © 2018 American Journal of Preventive Medicine. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30777162     DOI: 10.1016/j.amepre.2018.10.029

Source DB:  PubMed          Journal:  Am J Prev Med        ISSN: 0749-3797            Impact factor:   5.043


  5 in total

1.  Effects of the e-Motivate4Change Program on Metabolic Syndrome in Young Adults Using Health Apps and Wearable Devices: Quasi-Experimental Study.

Authors:  Ji-Soo Lee; Min-Ah Kang; Soo-Kyoung Lee
Journal:  J Med Internet Res       Date:  2020-07-30       Impact factor: 5.428

2.  Ideal cardiovascular health status and risk of cardiovascular disease and all-cause mortality: over a decade of follow-up in the Tehran lipid and glucose study.

Authors:  Farzad Hadaegh; Somayeh Hosseinpour-Niazi; Niloofar Deravi; Mitra Hasheminia; Nazanin Moslehi; Hossein Toreyhi; Fereidoun Azizi
Journal:  Front Cardiovasc Med       Date:  2022-08-04

Review 3.  Ethnicity and Metabolic Syndrome: Implications for Assessment, Management and Prevention.

Authors:  Scott A Lear; Danijela Gasevic
Journal:  Nutrients       Date:  2019-12-19       Impact factor: 5.717

4.  Long-term effectiveness of a lifestyle intervention on the prevention of type 2 diabetes in a middle-income country.

Authors:  Mojtaba Lotfaliany; Mohamad Ali Mansournia; Fereidoun Azizi; Farzad Hadaegh; Neda Zafari; Arash Ghanbarian; Parvin Mirmiran; Brian Oldenburg; Davood Khalili
Journal:  Sci Rep       Date:  2020-08-25       Impact factor: 4.379

5.  Sudden cardiac death among Iranian population: a two decades follow-up of Tehran lipid and glucose study.

Authors:  Hossein Toreyhi; Samaneh Asgari; Davood Khalili; Mehdi Pishgahi; Fereidoun Azizi; Farzad Hadaegh
Journal:  Sci Rep       Date:  2021-08-03       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.